Cyclosporine Market Report 2026

Cyclosporine Market Overview

• Cyclosporine market size has reached to $2.98 billion in 2025 • Expected to grow to $5.46 billion in 2030 at a compound annual growth rate (CAGR) of 12.8% • Growth Driver: Growing Prevalence Of Autoimmune Diseases Fueling The Growth Of The Market Due To Rising Demand For Immunosuppressants • Market Trend: Regulatory Approvals Drive Innovation And Market Expansion For Cyclosporine • Asia-Pacific was the largest region in 2025 and North America is the fastest growing region.

What Is Covered Under Cyclosporine Market?

Cyclosporine is an immunosuppressant medication primarily used to prevent organ transplant rejection and to treat certain autoimmune conditions. It works by inhibiting the activity of T-cells through the suppression of the enzyme calcineurin, thereby reducing inflammation and immune responses. It is also used in ophthalmic formulations to treat eye conditions such as dry eye disease. The main types of indications for cyclosporine are transplant rejection prophylaxis, rheumatoid arthritis, psoriasis, autoimmune myasthenia gravis, dry eye, and others. Transplant rejection prophylaxis is the use of cyclosporine to prevent the immune system from rejecting transplanted organs, such as kidneys, livers, or hearts. It includes various dosage forms such as capsules, eye drops, liquid solutions, creams, and ointments and is administered through various routes including oral, topical, and parenteral. It is distributed through hospital pharmacies, retail pharmacies, and online pharmacies catering to end users, such as hospitals, homecare, specialty centers, and others.

What Is The Cyclosporine Market Growth Forecast?

The cyclosporine market size is expected to see rapid growth in the next few years. It will grow to $5.46 billion in 2030 at a compound annual growth rate (CAGR) of 12.8%. The growth in the forecast period can be attributed to rising chronic autoimmune conditions, expanding ophthalmic disease burden, increasing transplant survival rates, wider availability of generics, growing outpatient immunosuppressive therapy use. Major trends in the forecast period include expanding use in autoimmune disease management, growing adoption of ophthalmic cyclosporine formulations, rising demand for long-term immunosuppressive therapies, increased use in organ transplant maintenance regimens, growth of generic cyclosporine products.

Global Cyclosporine Market Segmentation

1) By Indication: Transplant Rejection Prophylaxis, Rheumatoid Arthritis, Psoriasis, Autoimmune Myasthenia Gravis, Dry Eye, Other Indications 2) By Dosage Form: Capsule, Eye Drops, Liquid Solutions, Creams And Ointments 3) By Route Of Administration: Oral, Topical, Parenteral 4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 5) By End-Users: Hospitals, Homecare, Speciality Centres, Other End-Users Subsegments: 1) By Transplant Rejection Prophylaxis: Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant, Other Transplants 2) By Rheumatoid Arthritis: Moderate Rheumatoid Arthritis, Severe Rheumatoid Arthritis 3) By Psoriasis: Plaque Psoriasis, Erythrodermic Psoriasis, Guttate Psoriasis, Pustular Psoriasis 4) By Autoimmune Myasthenia Gravis: Generalized Myasthenia Gravis, Ocular Myasthenia Gravis 5) By Dry Eye: Chronic Dry Eye, Severe Dry Eye 6) By Other Indications: Atopic Dermatitis, Uveitis, Nephrotic Syndrome, Inflammatory Bowel Disease (IBD)

What Is The Driver Of The Cyclosporine Market?

The growing prevalence of autoimmune diseases is expected to propel the growth of the cyclosporine market going forward. Autoimmune diseases refer to conditions where the immune system mistakenly attacks the body's own cells, causing inflammation, tissue damage, and chronic illness. The rising prevalence of autoimmune diseases can be attributed to genetic predisposition, as advances in genetic testing have identified more individuals with hereditary risks, making them more susceptible to these conditions. Cyclosporine is effective for autoimmune diseases by suppressing T-cell activation, thereby reducing harmful immune responses against healthy tissues in conditions such as rheumatoid arthritis, psoriasis, and lupus. For instance, in October 2024, according to a comprehensive review published by Signal Transduction and Targeted Therapy, a journal published by Nature, a UK-based peer-reviewed scientific publisher, approximately 8.4 million patients suffer from rheumatoid arthritis worldwide, with the total incidence rate increasing by 2-3% annually; according to the Markov model approach, the affected populations are predicted to reach approximately 13.5-17.4 million by 2040. Therefore, the growing prevalence of autoimmune diseases is driving the growth of the cyclosporine industry.

Key Players In The Global Cyclosporine Market

Major companies operating in the cyclosporine market are Novartis AG, Viatris Inc., Teva Pharmaceutical Industries Ltd, Sandoz International GmbH, Sun Pharmaceutical Industries Ltd, Apotex Inc., Cipla Ltd, Dr. Reddy's Laboratories Ltd, Lupin Limited, Glenmark Pharmaceuticals Ltd, Taj Pharmaceuticals Limited, Panacea Biotec Ltd, Novaliq GmbH, Simson Pharma Limited, Strides Pharma Science Ltd, AdvaCare Pharma, JoinHub Pharma, Grevis Pharmaceuticals Pvt Ltd, GMT Pharma International, Logos Pharma.

Global Cyclosporine Market Trends and Insights

Major companies operating in the cyclosporine market are focusing on obtaining regulatory approvals to expand their product portfolios and enhance their market presence. Regulatory approvals for cyclosporine validate its safety and efficacy, enabling market access and boosting prescriber and patient confidence. For instance, in June 2023, Novaliq GmbH, a Germany-based biopharmaceutical company, received approval from the U.S. FDA for VEVYE (cyclosporine ophthalmic solution) 0.1%, a unique water-free ophthalmic drug developed for the treatment of dry eye disease (DED). It is the first and only cyclosporine-based solution for this condition, showing efficacy within just four weeks. VEVYE employs an innovative water-free technology known as EyeSol, which improves cyclosporine’s bioavailability and retention time on the ocular surface without the use of preservatives, oils, or surfactants. The solution functions as a calcineurin inhibitor, helping reduce inflammation linked to dry eye disease.

What Are Latest Mergers And Acquisitions In The Cyclosporine Market?

In July 2024, Lupin Limited, an India-based pharmaceutical company, partnered with Huons Co. Ltd. to launch a cyclosporine ophthalmic nanoemulsion in Mexico. This partnership aims to commercialize the product as an innovative treatment for dry eye syndrome and ocular inflammation, strengthening Lupin’s ophthalmology portfolio and enhancing patient care. Huons Co. Ltd. is a South Korea-based pharmaceutical company actively engaged in the development and commercialization of cyclosporine-based ophthalmic therapies.

Regional Insights

Asia-Pacific was the largest region in the cyclosporine market in 2025. North America is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Cyclosporine Market?

The cyclosporine market consists of sales of injectable cyclosporine, ophthalmic formulations, intravenous solutions, topical formulations, and oral solutions. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Cyclosporine Market Report 2026?

The cyclosporine market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the cyclosporine industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.